Stryker Corporation (SYK) Position Reduced by Quantitative Investment Management LLC

Quantitative Investment Management LLC cut its holdings in Stryker Corporation (NYSE:SYK) by 75.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,000 shares of the medical technology company’s stock after selling 81,800 shares during the period. Quantitative Investment Management LLC’s holdings in Stryker Corporation were worth $3,608,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Bollard Group LLC lifted its holdings in Stryker Corporation by 0.4% in the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after acquiring an additional 3 shares during the last quarter. Assetmark Inc. lifted its holdings in Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after acquiring an additional 4 shares during the last quarter. Blue Chip Partners Inc. lifted its holdings in Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock valued at $234,000 after acquiring an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America lifted its holdings in Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after acquiring an additional 9 shares during the last quarter. Finally, FineMark National Bank & Trust lifted its holdings in Stryker Corporation by 0.4% in the second quarter. FineMark National Bank & Trust now owns 3,878 shares of the medical technology company’s stock valued at $538,000 after acquiring an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 74.13% of the company’s stock.

A number of research analysts recently commented on SYK shares. Morgan Stanley upped their price objective on Stryker Corporation from $145.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, June 21st. Royal Bank Of Canada reiterated a “buy” rating and issued a $155.00 price objective on shares of Stryker Corporation in a report on Friday, September 1st. Argus reiterated a “buy” rating and issued a $160.00 price objective on shares of Stryker Corporation in a report on Tuesday, August 29th. Cantor Fitzgerald started coverage on Stryker Corporation in a report on Thursday, June 29th. They issued a “neutral” rating and a $153.00 price objective on the stock. Finally, BidaskClub cut Stryker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. Stryker Corporation presently has an average rating of “Hold” and a consensus price target of $146.78.

In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now owns 88,207 shares in the company, valued at approximately $12,909,976.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. Insiders own 7.40% of the company’s stock.

WARNING: This piece was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/11/stryker-corporation-syk-position-reduced-by-quantitative-investment-management-llc.html.

Stryker Corporation (NYSE SYK) opened at 144.69 on Wednesday. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $149.23. The firm’s 50-day moving average price is $142.48 and its 200-day moving average price is $140.29. The firm has a market capitalization of $54.12 billion, a PE ratio of 32.30 and a beta of 0.80.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same period in the previous year, the company earned $1.39 EPS. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, equities research analysts predict that Stryker Corporation will post $6.45 EPS for the current fiscal year.

The firm also recently announc

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Bollard Group LLC lifted its holdings in Stryker Corporation by 0.4% in the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after acquiring an additional 3 shares during the last quarter. Assetmark Inc. lifted its holdings in Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after acquiring an additional 4 shares during the last quarter. Blue Chip Partners Inc. lifted its holdings in Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock valued at $234,000 after acquiring an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America lifted its holdings in Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after acquiring an additional 9 shares during the last quarter. Finally, FineMark National Bank & Trust lifted its holdings in Stryker Corporation by 0.4% in the second quarter. FineMark National Bank & Trust now owns 3,878 shares of the medical technology company’s stock valued at $538,000 after acquiring an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 74.13% of the company’s stock.

A number of research analysts recently commented on SYK shares. Morgan Stanley upped their price objective on Stryker Corporation from $145.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, June 21st. Royal Bank Of Canada reiterated a “buy” rating and issued a $155.00 price objective on shares of Stryker Corporation in a report on Friday, September 1st. Argus reiterated a “buy” rating and issued a $160.00 price objective on shares of Stryker Corporation in a report on Tuesday, August 29th. Cantor Fitzgerald started coverage on Stryker Corporation in a report on Thursday, June 29th. They issued a “neutral” rating and a $153.00 price objective on the stock. Finally, BidaskClub cut Stryker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. Stryker Corporation presently has an average rating of “Hold” and a consensus price target of $146.78.

In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now owns 88,207 shares in the company, valued at approximately $12,909,976.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. Insiders own 7.40% of the company’s stock.

WARNING: This piece was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/11/stryker-corporation-syk-position-reduced-by-quantitative-investment-management-llc.html.

Stryker Corporation (NYSE SYK) opened at 144.69 on Wednesday. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $149.23. The firm’s 50-day moving average price is $142.48 and its 200-day moving average price is $140.29. The firm has a market capitalization of $54.12 billion, a PE ratio of 32.30 and a beta of 0.80.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same period in the previous year, the company earned $1.39 EPS. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, equities research analysts predict that Stryker Corporation will post $6.45 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be issued a dividend of $0.425 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.17%. Stryker Corporation’s payout ratio is 37.95%.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply